Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state through the expression of certain genes. The reprogramming allows these cells to differentiate into specialized cell types which gives them properties similar to embryonic stem cells but without the need for human embryos. iPSCs have valuable advantages such as unlimited self-renewal ability and the capacity to differentiate into all cell types of the body such as neurons, heart muscle cells, pancreatic cells, etc. This property renders them useful for drug discovery and toxicity testing, modeling diseases and regenerative medicine. The Global Induced Pluripotent Stem Cells Market is estimated to be valued at US$ 1,595.4 MN in 2024 and is expected to exhibit a CAGR of 1.4% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Global Induced Pluripotent Stem Cells Market Growth are Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines and Other Prominent Players. The increasing prevalence of chronic diseases worldwide is fueling the demand for stem cell-based treatment. Over the past few years, there has been substantial progress in induced pluripotent stem cell technologies that have enabled more facile and efficient reprogramming and differentiation of cells. This advancement is further propelling the market growth.

Market Trends

Cell therapy products derived from iPSCs are gaining traction - Companies are developing specialized cell types such as retinal pigment epithelial cells for macular degeneration, cardiomyocytes for heart disease, and motor neurons for ALS derived from iPSCs for cell therapy. 3D organoid technology - Organoids are 3D cell culture models that mimic human organs and physiology. Researchers are developing liver, pancreas, brain and other organoids from iPSCs to model diseases and test drugs. This trend is expected to grow further during the forecast period.

Market Opportunities

Regenerative medicine - Considerable research is ongoing to explore the clinical potential of iPSCs for regenerating tissues damaged by injury or disease conditions like heart disease, diabetes, Parkinson's. Personalized medicine - Generation of patient-specific iPSCs opens opportunities for developing personalized disease models and customized cell therapies. This reduces rejection risks in therapy while improving outcomes.

Impact of COVID-19 on Global Induced Pluripotent Stem Cells Market

The COVID-19 pandemic has significantly impacted the growth of the global induced pluripotent stem cells market. During the initial stages of the pandemic, many research activities involving stem cell therapies were put on hold due to funding constraints and temporary closure of research laboratories. This led to decline in demand for induced pluripotent stem cells. However, as induced pluripotent stem cells have potential to aid in drug discovery and development of vaccines and treatments for COVID-19, investments started pouring in stem cell research from late 2020. Researchers are exploring the possibility of utilizing IPSC-derived lung and airway epithelial cell models to understand pathogenesis of SARS-CoV-2 virus. Some studies have also shown potential of IPSC-derived cardiomyocytes to recapitulate COVID-19-related cardiac alterations. With increasing R&D in this direction, demand for induced pluripotent stem cells is anticipated to grow steadily in the forecast period. Industry players are also expected to focus on strengthening their product portfolios and facilitating collaborations with pharma companies and research institutes to aid COVID-19 research.

Geographical Regions with High Concentration of Global Induced Pluripotent Stem Cells Market

North America holds the largest share of the global induced pluripotent stem cells market, in terms of value. This is attributable to presence of major players, strong biotech industry, and rising stem cell research funding in the US. According to the International Society for Stem Cell Research, the US invested over US$ 2 billion in stem cell research in 2020 alone. Japan also accounts for a significant market share owing to early adoption of IPSC technology and growing number of clinical trials for stem cell-based therapies in the country. Other regions such as Europe and Asia Pacific are anticipated to witness high growth during the forecast period, due to increasing focus of governments as well as private organizations on stem cell research.

Fastest Growing Region in Global Induced Pluripotent Stem Cells Market

Asia Pacific region is poised to be the fastest growing region in the global induced pluripotent stem cells market during the forecast period. This is majorly attributed to emerging economies like China and India aggressively investing in life sciences sector to strengthen their indigenous stem cell R&D capabilities. Favorable regulatory environment and growing stem cell banking industry are also supporting market growth. In addition, increasing collaborations between Asian and international companies for development of novel stem cell-based applications will aid the market expansion. Development of specialized stem cell clusters or parks with state-of-art research infrastructure by various Asian governments is anticipated to attract more global players to establish manufacturing and distribution channels in this region. All these factors are projected to drive high growth of induced pluripotent stem cells market in Asia Pacific.

Get more insights on Global Induced Pluripotent Stem Cells Market